IL225018A - Beta tgf barriers for use in reducing myocardial infarction - Google Patents
Beta tgf barriers for use in reducing myocardial infarctionInfo
- Publication number
- IL225018A IL225018A IL225018A IL22501813A IL225018A IL 225018 A IL225018 A IL 225018A IL 225018 A IL225018 A IL 225018A IL 22501813 A IL22501813 A IL 22501813A IL 225018 A IL225018 A IL 225018A
- Authority
- IL
- Israel
- Prior art keywords
- reducing
- myocardial infarction
- tgf beta
- adverse consequence
- beta antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37931510P | 2010-09-01 | 2010-09-01 | |
| PCT/US2011/001536 WO2012030394A1 (en) | 2010-09-01 | 2011-09-01 | Treatment of myocardial infarction using tgf - beta antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL225018A true IL225018A (en) | 2017-11-30 |
Family
ID=44654454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL225018A IL225018A (en) | 2010-09-01 | 2013-02-28 | Beta tgf barriers for use in reducing myocardial infarction |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20130330352A1 (https=) |
| EP (1) | EP2611831B1 (https=) |
| JP (2) | JP6377348B2 (https=) |
| KR (1) | KR101939965B1 (https=) |
| CN (1) | CN103201292B (https=) |
| BR (1) | BR112013004850B1 (https=) |
| CA (1) | CA2809568C (https=) |
| CL (1) | CL2013000586A1 (https=) |
| ES (1) | ES2715177T3 (https=) |
| IL (1) | IL225018A (https=) |
| MX (1) | MX354535B (https=) |
| MY (1) | MY165160A (https=) |
| NZ (2) | NZ608813A (https=) |
| PH (1) | PH12013500411A1 (https=) |
| PL (1) | PL2611831T3 (https=) |
| RU (1) | RU2637088C2 (https=) |
| SG (2) | SG187953A1 (https=) |
| TR (1) | TR201903101T4 (https=) |
| WO (1) | WO2012030394A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1008628A2 (pt) * | 2009-02-18 | 2016-03-01 | Cormatrix Cardiovascular Inc | método de tratamento ou prevenção de arritmia cardíaca em um indivíduo |
| PT2971048T (pt) * | 2013-03-11 | 2019-02-06 | Genzyme Corp | Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios |
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| HK1256638A1 (zh) | 2015-08-04 | 2019-09-27 | Acceleron Pharma Inc. | 用於治疗骨髓增生性病症的方法 |
| DK3368571T5 (da) | 2015-10-30 | 2024-09-30 | Univ California | Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf |
| TW201726744A (zh) | 2016-01-11 | 2017-08-01 | 奧托德里克有限公司 | 用於檢測奧美沙坦(olmesartan)及改善治療高血壓之遵從性的組成物、裝置及方法 |
| US20170218040A1 (en) * | 2016-02-02 | 2017-08-03 | Julio A. Camarero Palao | Proteolically resistant cyclotides with angiotensin 1-7 like activity |
| JP2019533003A (ja) * | 2016-08-11 | 2019-11-14 | プレシセラ，インコーポレイテッド | ＴＧＦ−βアンタゴニストコンジュゲート |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| AU2021339468A1 (en) * | 2020-09-10 | 2023-03-30 | Implicit Bioscience Limited | Therapeutic methods and agents for the treatment of myocardial infarction |
| US20250034212A1 (en) | 2021-09-30 | 2025-01-30 | Peptidream Inc. | Peptide |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| US7763580B2 (en) * | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| CN1961003B (zh) * | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| WO2006083779A2 (en) | 2005-01-31 | 2006-08-10 | Mylan Laboratories, Inc. | Pharmaceutical composition comprising hydroxylated nebivolol |
| WO2006086469A2 (en) * | 2005-02-08 | 2006-08-17 | Genzyme Corporation | Antibodies to tgfbeta |
| AU2010206543A1 (en) * | 2009-01-26 | 2011-07-07 | Intermune, Inc. | Methods for treating acute myocardial infarctions and associated disorders |
| ITMI20110376A1 (it) | 2011-03-10 | 2012-09-11 | Wilic Sarl | Aerogeneratore raffreddato a fluido |
-
2011
- 2011-09-01 MY MYPI2013000675A patent/MY165160A/en unknown
- 2011-09-01 NZ NZ608813A patent/NZ608813A/en not_active IP Right Cessation
- 2011-09-01 CN CN201180052346.0A patent/CN103201292B/zh not_active Expired - Fee Related
- 2011-09-01 WO PCT/US2011/001536 patent/WO2012030394A1/en not_active Ceased
- 2011-09-01 EP EP11758276.7A patent/EP2611831B1/en active Active
- 2011-09-01 PH PH1/2013/500411A patent/PH12013500411A1/en unknown
- 2011-09-01 MX MX2013002390A patent/MX354535B/es active IP Right Grant
- 2011-09-01 CA CA2809568A patent/CA2809568C/en not_active Expired - Fee Related
- 2011-09-01 TR TR2019/03101T patent/TR201903101T4/tr unknown
- 2011-09-01 US US13/819,393 patent/US20130330352A1/en not_active Abandoned
- 2011-09-01 RU RU2013114365A patent/RU2637088C2/ru active
- 2011-09-01 SG SG2013013875A patent/SG187953A1/en unknown
- 2011-09-01 NZ NZ624382A patent/NZ624382A/en not_active IP Right Cessation
- 2011-09-01 KR KR1020137008326A patent/KR101939965B1/ko not_active Expired - Fee Related
- 2011-09-01 ES ES11758276T patent/ES2715177T3/es active Active
- 2011-09-01 BR BR112013004850A patent/BR112013004850B1/pt not_active IP Right Cessation
- 2011-09-01 PL PL11758276T patent/PL2611831T3/pl unknown
- 2011-09-01 JP JP2013527063A patent/JP6377348B2/ja not_active Expired - Fee Related
- 2011-09-01 SG SG10201506909PA patent/SG10201506909PA/en unknown
-
2013
- 2013-02-28 CL CL2013000586A patent/CL2013000586A1/es unknown
- 2013-02-28 IL IL225018A patent/IL225018A/en active IP Right Grant
-
2016
- 2016-12-12 US US15/376,358 patent/US10633437B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 JP JP2017083499A patent/JP2017193543A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL225018A (en) | Beta tgf barriers for use in reducing myocardial infarction | |
| PL2927224T3 (pl) | Antagoniści receptora | |
| AP3391A (en) | 2-Amino-4-arylthiazole compounds as TROA1 antagonists | |
| ZA201500215B (en) | Inhibitors of the fibroblast growth factor receptor | |
| ZA201204966B (en) | Inter-frequency positioning measurements | |
| ZA201207292B (en) | Cgrp receptor antagonist | |
| GB201004554D0 (en) | Superconducting materials | |
| ZA201308816B (en) | Trpv4 antagonists | |
| IL224435B (en) | Agonists and chimeric antagonists for the 1-il receptor type 1 | |
| GB201410398D0 (en) | Muscarinic m1 receptor agonists | |
| GB2480614B (en) | Switched arrangement for switched mode supply | |
| EP2720546A4 (en) | TRPV4 Antagonist | |
| HUE039607T2 (hu) | Progeszteron antagonisták | |
| ZA201305576B (en) | Trpm8 receptor antagonists | |
| IL232503A (en) | H2 - Indazoles as antagonists of the ep2 receptor | |
| EP2620160A4 (en) | COMPOSITIONS FOR ORAL ADMINISTRATION | |
| EP2720697A4 (en) | TRPV4 Antagonist | |
| EP2549872A4 (en) | TRPV4 Antagonist | |
| ZA201301561B (en) | 5-ht2b receptor antagonists | |
| TWM385441U (en) | Structure for hand tool | |
| GB201008323D0 (en) | Telescopic art kiosk | |
| GB201008486D0 (en) | Powder dispenser for use with consumable goods | |
| GB0922455D0 (en) | Ep2 receptor antagonists | |
| GB201017282D0 (en) | Agents for use with antimicrobials | |
| GB201005633D0 (en) | Tool for retrieving detachable flat mopping layers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |